Logo

Sanofi's Dupixent (dupilumab) Receives EC's Approval for Children with Severe Atopic Dermatitis

Share this

Sanofi's Dupixent (dupilumab) Receives EC's Approval for Children with Severe Atopic Dermatitis

Shots:

  • The EC’s approval is based on a P-III study assessing Dupixent (300mg- q4w & 200mg- q2w) + TCS vas TCS alone in children aged 6-11yrs. with severe AD
  • Result: improvement in disease extent and severity (82% & 80% vs 49% & 48%); at least 75% improvement (70% & 75% vs 17% & 26%); skin clearance (33% & 39% vs 11% & 10%); reduction in itching (51% & 61% vs 12% & 13%); improvement in HR-QoL (77% & 81% vs 39% & 36%) respectively
  • Dupixent is mAb that inhibits the signaling of IL-4 and IL-13 proteins and is the only systemic medicine approved in the EU to treat children with severe AD

 ­ Ref: Sanofi | Image: BioSpace

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions